ArticleEuropean journal of microbiology & immunology2025
Topical microemulsion with phenolic compounds from Libidibia ferrea (Fabaceae): An alternative treatment for cutaneous leishmaniasis.
Article in European journal of microbiology & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cutaneous leishmaniasis: emerging insights in epidemiology, diagnosis, and treatment.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pharmacotherapy of cutaneous leishmaniasis is invasive and presents several adverse reactions, which reinforces the need for topical and less toxic alternatives. Methods: Topical microemulsions containing phenolic compounds from Libidibia ferrea (Fabaceae) were developed, physicochemically characterized, and tested in hamsters (Mesocricetus auratus) experimentally infected with Leishmania amazonensis. After treatment, clinical progression of lesions, histopathological alterations, and parasite load were evaluated. The dichloromethane (DCM) fraction of the extract was analyzed by mass spectrometry, and the main compounds were isolated. Results: The optimized microemulsion effectively controlled lesion progression, showing only a 25% increase in lesion volume, compared to a 383% increase for the group without treatment, and presented a moderate inflammatory response. A new phenolic compound, named libidine (phenylpropanoic acid derivative), along with methyl gallate, was isolated from the DCM fraction. Conclusions: The topical formulation was as effective as Glucantime® (antimonial standard treatment) and produced a significant reduction in parasite load, consistent with the antileishmanial activity previously reported for phenolic acids and their derivatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.